Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey A Carter

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Journal of Investigative Medicine High Impact Case Reports|August 8, 2018
Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable CancerBryan Oronsky, Chris Larson, Tony R Reid, et al.
Neoplasia (New York, N.Y.)|November 2, 2017
Nothing But NET: A Review of Neuroendocrine Tumors and CarcinomasBryan Oronsky, Patrick C Ma, Daniel Morgensztern, et al.
Case Reports in Oncology|November 25, 2015
Dysphonia after Bevacizumab Rechallenge: A Case ReportCorey A Carter, Scott Z Caroen, Arnold L Oronsky, et al.
Case Reports in Oncology|May 31, 2016
Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?Corey A Carter, Jan J Scicinski, Harry E Lybeck, et al.
Case Reports in Oncology|March 3, 2016
The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced PneumonitisCorey A Carter, Robert Browning, Bryan T Oronsky, et al.
Case Reports in Oncology|June 15, 2017
Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case ReportChristina Brzezniak, Bryan Oronsky, Corey A Carter, et al.
Oncoimmunology|January 18, 2021
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"Bryan Oronsky, Corey A Carter, Scott Caroen, et al.
Oncotarget|May 29, 2018
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cellsBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
Medical Oncology (Northwood, London, England)|May 1, 2016
"No patient left behind": an alternative to "the War on Cancer" metaphorBryan T Oronsky, Corey A Carter, Arnold L Oronsky, et al.
Molecular Pharmaceutics|May 1, 2019
Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in MiceBryan Oronsky, Eilleen S Y Ao-Ieong, Ozlem Yalcin, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Journal of Investigative Medicine High Impact Case Reports|August 8, 2018
Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable CancerBryan Oronsky, Chris Larson, Tony R Reid, et al.
Neoplasia (New York, N.Y.)|November 2, 2017
Nothing But NET: A Review of Neuroendocrine Tumors and CarcinomasBryan Oronsky, Patrick C Ma, Daniel Morgensztern, et al.
Case Reports in Oncology|November 25, 2015
Dysphonia after Bevacizumab Rechallenge: A Case ReportCorey A Carter, Scott Z Caroen, Arnold L Oronsky, et al.
Case Reports in Oncology|May 31, 2016
Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?Corey A Carter, Jan J Scicinski, Harry E Lybeck, et al.
Case Reports in Oncology|March 3, 2016
The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced PneumonitisCorey A Carter, Robert Browning, Bryan T Oronsky, et al.
Case Reports in Oncology|June 15, 2017
Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case ReportChristina Brzezniak, Bryan Oronsky, Corey A Carter, et al.
Oncoimmunology|January 18, 2021
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"Bryan Oronsky, Corey A Carter, Scott Caroen, et al.
Oncotarget|May 29, 2018
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cellsBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
Medical Oncology (Northwood, London, England)|May 1, 2016
"No patient left behind": an alternative to "the War on Cancer" metaphorBryan T Oronsky, Corey A Carter, Arnold L Oronsky, et al.
Molecular Pharmaceutics|May 1, 2019
Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in MiceBryan Oronsky, Eilleen S Y Ao-Ieong, Ozlem Yalcin, et al.
Pageof 6